The European Commission has approved Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma, supported by Phase II FIREFLY-1 trial data showing durable responses and a manageable safety profile.
Written By: Dr. Anuja Badgujar, BDS
Reviewed By: Pharmacally Editorial Team
European Commission has granted conditional marketing authorization for Ojemda (tovorafenib), an oral targeted therapy, for the treatment of patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring BRAF fusion or rearrangement, or BRAF V600 mutation, following at least one prior systemic therapy.
The decision applies across all European Union Member States as well as Iceland, Liechtenstein, and Norway.
Clinical evidence supporting the approval comes from the Phase II FIREFLY-1 trial (NCT04775485), which evaluated the drug in pediatric patients whose disease had progressed after at least one prior therapy.
The study demonstrated clinically meaningful and durable responses, with overall response rates ranging from approximately 50% to 70% and responses observed across molecular subtypes.
Many responses were ongoing at the time of analysis, and treatment was associated with tumor shrinkage as well as improvements in neurological symptoms and reduced corticosteroid use.
Early findings also suggest favorable progression-free survival, with a substantial proportion of patients remaining progression-free at 12 months.
Tovorafenib is a central nervous system–penetrant, type II RAF kinase inhibitor that selectively targets aberrant MAPK pathway signaling. Unlike earlier RAF inhibitors, it demonstrates activity across a broader spectrum of RAF alterations, supporting its use across multiple molecular subtypes of pediatric low-grade glioma (pLGG).
Pediatric low-grade glioma, though classified as a slow-growing tumor, carries a substantial long-term burden. More than 800 children in Europe are diagnosed annually with BRAF-altered disease, and many experience lasting neurological and functional impairments such as vision loss, speech difficulties, and motor dysfunction that can affect independence and quality of life.
Treatment has traditionally relied on surgery, chemotherapy, and radiotherapy, often requiring repeated interventions and exposing patients to significant long-term toxicities.
The therapy showed a manageable safety profile consistent with RAF inhibition, with commonly reported adverse events including hair color changes, rash, elevated creatine phosphokinase, and fatigue.
Most events were mild to moderate in severity and reversible, and treatment discontinuation rates were low, supporting its suitability for long-term use in pediatric patients.
Overall, this approval marks an important step forward in the treatment of relapsed or refractory pediatric low-grade glioma by introducing a targeted therapy with durable clinical benefit and a tolerable safety profile.
It expands treatment options beyond conventional approaches and may help reduce reliance on therapies associated with long-term morbidity in children.
Reference
About the Writer
Dr. Anuja Badgujar, BDS is a dentist with expertise in US healthcare data and medical data annotation. With four years of experience handling US healthcare datasets, she brings strong domain knowledge and precision to her work. She is also deeply passionate about medical writing, with a focus on translating complex medical information into clear and structured content.